Published in Cancer Weekly, October 11th, 2005
"Intravenous (IV) infusion of unfractionated, heparin (UFH) followed by oral administration of warfarin remains the cornerstone of clinical treatment of deep vein thrombosis (DVT). Results from numerous clinical trials demonstrate that subcutaneously administered LMWH is at least as effective and as safe as IV UFH," scientists writing in the American Journal of Medicine reported.
"Treatment with LMWH has several clinical advantages over treatment with UFH, including less-frequent dosing and elimination of the need for monitoring. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.